ArticleNature cancer2021
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 32 citations in OpenAlex.
- T cell lymphomas: cancers of aberrant immune synapse signalling.Nature reviews. Immunology · 2026Review
- Case Report: Cutaneous niche-restricted malignant phenotypes in PTCL-NOS revealed by single-cell sequencing.Frontiers in oncology · 2026Article
- Spatiotemporal profiling of modification-specific proteome secretion uncovers an itaconation-activated tyrosine kinase.Nature communications · 2025Article
- Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma.American journal of hematology · 2025Article
- Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB.International journal of hematology · 2025Article
- Assessing the impact of TET2 and TET3 deletion in TCRalpha and TCRbeta repertoire in murine CD4 T cells in physiological and pathophysiological conditions.Frontiers in immunology · 2025Article
- Advancing the understanding and management of angioimmunoblastic T-cell lymphoma: insights into its pathogenesis, clinical features, and emerging therapeutic strategies.Frontiers in oncology · 2025Review
- Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells.Cancer discovery · 2024Article
- 5-Hydroxymethylcytosine Profiles of cfDNA in Urine as Diagnostic, Differential Diagnosis and Prognostic Markers for Multiple Myeloma.Cancer medicine · 2024Article
- Review
- Single-cell transcriptome sequencing reveals SPP1-CD44-mediated macrophage-tumor cell interactions drive chemoresistance in TNBC.Journal of cellular and molecular medicine · 2024Article
- Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.Journal of hematology & oncology · 2024Review
- Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.Haematologica · 2023Review
- Article
- Advances in the expression and function of Fyn in different human tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target.Clinical lymphoma, myeloma & leukemia · 2023Review
- Role of Fyn in hematological malignancies.Journal of cancer research and clinical oncology · 2023Review
- FYN: emerging biological roles and potential therapeutic targets in cancer.Journal of translational medicine · 2023Review
- Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL).Frontiers in oncology · 2023Review
- Tyrosine kinases in nodal peripheral T-cell lymphomas.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 2 countries.
Christine S Moon *Institute for Cancer Genetics, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0001-8717-2435
Clara Reglero *Institute for Cancer Genetics, Columbia University, New York, NY, USA.
Jose R Cortes *Institute for Cancer Genetics, Columbia University, New York, NY, USA.
S Aidan QuinnInstitute for Cancer Genetics, Columbia University, New York, NY, USA.
Silvia AlvarezInstitute for Cancer Genetics, Columbia University, New York, NY, USA.
Junfei ZhaoDepartment of Systems Biology, Columbia University, New York, NY, USA.
Wen-Hsuan W LinDepartment of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5414-7900
Anisha J CookeInstitute for Cancer Genetics, Columbia University, New York, NY, USA.
Francesco AbateDepartment of Systems Biology, Columbia University, New York, NY, USA.
Craig R SoderquistDepartment of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.
Claudia FiñanaInstitute for Cancer Genetics, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0003-2554-1498
Giorgio InghiramiDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0001-5566-0864
Elias CampoDepartment of Pathology, Hospital Clinic of Barcelona, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Govind BhagatDepartment of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-6250-048X
Raul RabadanDepartment of Systems Biology, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7946-9255
Teresa PalomeroInstitute for Cancer Genetics, Columbia University, New York, NY, USA. tp2151@columbia.edu.ORCID http://orcid.org/0000-0001-9851-3207
Adolfo A FerrandoInstitute for Cancer Genetics, Columbia University, New York, NY, USA. af2196@columbia.edu.ORCID http://orcid.org/0000-0002-6212-8574
Cancer Genetics (United States) · USColumbia University Irving Medical Center · USColumbia University · USConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESCornell University · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MNation Center: Multi-Scale Study- Cellular Networks(RMI)U54CA121852 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2005 to 2015
$37.4MPreclinical Models and Therapeutics CoreP01CA229100 · NCI · MAYO CLINIC ARIZONA · PI FELDMAN, ANDREW LEWIS · 2018 to 2022
$10.2MMolecular pathways and targeted therapies in human leukemiaR35CA210065 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FERRANDO, ADOLFO A. · 2017 to 2021
$4.7MIdentification and modeling of driver genetic modules in glioblastomaR01CA179044 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO, RABADAN, RAUL · 2014 to 2018
$2.3M(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic DataR01CA185486 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LASORELLA, ANNA, RABADAN, RAUL · 2014 to 2017
$2.1MMolecular characterization and targeting of NT5C2 mutations in acute lymphoblastic leukemiaR01CA216981 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FERRANDO, ADOLFO A., STOCKWELL, BRENT R. · 2017 to 2021
$1.9MThe role of RHOA G17V mutation in peripheral t-cell lymphomasR01CA197945 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PALOMERO, TERESA · 2015 to 2019
$1.8MCAPRI: Columbia Cancer Training Program for Resident-InvestigatorsR38CA231577 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CREW, KATHERINE D, SCHWARTZ, GARY K · 2018 to 2021
$1.4MThe role of a novel fusion oncogene FYN-TRAF3IP2 in peripheral T-cell lymphomaF30CA225052 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOON, CHRISTINE SHEILA · 2018 to 2021
$169kNCI NIH HHS F30 CA225052NCI NIH HHS P01 CA229100NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA179044NCI NIH HHS R01 CA185486NCI NIH HHS R01 CA197945NCI NIH HHS R01 CA216981NCI NIH HHS R35 CA210065NCI NIH HHS R38 CA231577NCI NIH HHS U54 CA121852
Abstract
Angioimmunoblastic T cell lymphoma (AITL) and peripheral T cell lymphoma not-otherwise-specified (PTCL, NOS) have poor prognosis and lack driver actionable targets for directed therapies in most cases. Here we identify
Indexed as
Immunoblastic LymphadenopathyLymphoma, T-Cell, PeripheralAdaptor Proteins, Signal TransducingAnimalsMiceNF-kappa BOncogenesSignal TransductionAdaptor Proteins, Signal TransducingNF-kappa BTraf3ip2 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.